Muscle GrowthHormone Optimization
Tesamorelin
FDA-approved GHRH analogue for visceral fat reduction
Overview
Tesamorelin is a synthetic form of Growth Hormone-Releasing Hormone (GHRH) modified with a trans-3-hexenoic acid group. It is the only peptide FDA-approved for reducing visceral adipose tissue (VAT) in HIV-associated lipodystrophy. Research extends its use to non-HIV populations for reducing belly fat, improving liver health (NAFLD), and potentially enhancing cognitive function in mild cognitive impairment.
Chemical Information
IUPAC Name
Trans-3-hexenoyl-GHRH (1-44)
Sequence
Hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular Mass
5135.9 Da
Formula
C221H366N72O67S
Mechanism of Action
Functions as a stabilized GHRH analogue. Its N-terminal modification (trans-3-hexenoic acid) protects it from degradation by the DPP-IV enzyme, giving it a longer half-life than natural GHRH. It binds to pituitary GHRH receptors to stimulate the production and release of endogenous Growth Hormone (GH) in a pulsatile, physiological manner. Uniquely, clinical data shows it specifically targets Visceral Adipose Tissue (VAT)—the dangerous deep fat around organs—more effectively than other secretagogues. It reduces liver fat (hepatic steatosis) and improves lipid profiles (lowering triglycerides and LDL) without significantly altering glucose control (HbA1c).
Potential Research Fields
Visceral AdiposityNAFLD / NASHHIV LipodystrophyCognitive Decline (MCI)Cardiovascular Risk
Recent Research
While approved for HIV-associated fat gain, recent research (2023–2025) strongly supports Tesamorelin's utility in the general population for Non-Alcoholic Fatty Liver Disease (NAFLD). A landmark study in The Lancet demonstrated that Tesamorelin significantly reduced liver fat content and prevented fibrosis progression better than lifestyle changes alone. Additionally, neurobiology researchers are revisiting its potential for Mild Cognitive Impairment (MCI). By restoring physiological GH and IGF-1 levels in the brain (which decline with age), studies suggest it enhances executive function and verbal memory, offering a dual benefit of metabolic and cognitive rejuvenation.
Bibliography / Scientific References
- [1]Tesamorelin reduces liver fat in NAFLDThe Lancet HIV • 2019 - Clinical trial showing significant reduction in hepatic adipose tissue.
- [2]Effects on cognition in Mild Cognitive ImpairmentArch Neurol • 2012 - Improved executive function and verbal memory in older adults.
Related Peptides
Peptide Information Guide
Administration Type
Injectable (Subcutaneous)Injectable administration protocol for research.
Vial Strength
10mg20mg
Reconstitution
Reconstitute with 2ml bacteriostatic water
Dosage Options
2 mg (40 units)
5 days/week
Protocol for 10mg vial reconstituted w/ 2ml water (5mg/ml)
3 mg (30 units)
5 days/week
Protocol for 20mg vial reconstituted w/ 2ml water (10mg/ml)
Schedule
5 days/week
Timing: One specific day.
Duration
3 Months
Potential Side Effects
Joint stiffness/pain
moderatecommon
Injection site redness
lowcommon
Research Use Only
This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.